(TSHA) Taysha Gene Therapies - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.578m USD | Total Return: 92.6% in 12m
Avg Turnover: 12.9M
Qual. Beats: 0
Rev. Trend: -72.4%
Qual. Beats: 0
Warnings
Share dilution 36.1% YoY
Interest Coverage Ratio -2478.7 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology firm headquartered in Dallas, Texas, specializing in adeno-associated virus (AAV) gene therapies. The company’s pipeline targets severe monogenic diseases of the central nervous system, with lead candidates including TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy. Its business model relies heavily on strategic partnerships, notably a research and collaboration agreement with The University of Texas Southwestern Medical Center to advance its therapeutic candidates.
The gene therapy sector focuses on long-term clinical solutions by delivering functional copies of genes to replace defective ones, a process that requires specialized manufacturing and high-cost R&D. As a clinical-stage entity, TSHA operates within a capital-intensive industry where valuation is primarily driven by regulatory milestones and clinical trial data rather than immediate revenue. You may find more detailed fundamental analysis for this ticker on ValueRay.
- Clinical data readouts for TSHA-102 in Rett syndrome drive short-term valuation
- Regulatory approval timelines for gene therapy pipeline determine long-term commercial viability
- Cash runway and future equity dilution risks impact investor sentiment
- Strategic partnership milestones with Astellas Pharma provide essential non-dilutive capital
- Scalability of AAV manufacturing processes influences operational costs and margins
| Net Income: -129.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 14.99 > 1.0 |
| NWC/Revenue: 3.51k% < 20% (prev 1.36k%; Δ 2.15k% < -1%) |
| CFO/TA -0.37 > 3% & CFO -111.9m > Net Income -129.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (366.6m) vs 12m ago 36.14% < -2% |
| Gross Margin: 84.51% > 18% (prev 0.83%; Δ 8.37k% > 0.5%) |
| Asset Turnover: 3.41% > 50% (prev 5.22%; Δ -1.82% > 0%) |
| Interest Coverage Ratio: -2.48k > 6 (EBITDA TTM -130.2m / Interest Expense TTM 53.0k) |
| A: 0.87 (Total Current Assets 282.2m - Total Current Liabilities 20.1m) / Total Assets 300.4m |
| B: -2.51 (Retained Earnings -753.7m / Total Assets 300.4m) |
| C: -0.60 (EBIT TTM -131.4m / Avg Total Assets 219.4m) |
| D: -8.51 (Book Value of Equity -752.7m / Total Liabilities 88.4m) |
| Altman-Z'' = -15.42 = D |
As of May 24, 2026, the stock is trading at USD 5.54 with a total of 2,171,234 shares traded.
Over the past week, the price has changed by -7.89%,
over one month by -18.30%,
over three months by +13.43% and
over the past year by +92.63%.
Taysha Gene Therapies has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy TSHA.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.2 | 120.8% |
P/B = 7.4368
Revenue TTM = 7.47m USD
EBIT TTM = -131.4m USD
EBITDA TTM = -130.2m USD
Long Term Debt = 49.0m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 68.6m USD (corrected: LT Debt 49.0m + ST Debt none) + Leases 19.6m
Net Debt = -161.2m USD (calculated: Debt 68.6m - CCE 229.7m)
Enterprise Value = 1.42b USD (1.58b + Debt 68.6m - CCE 229.7m)
Interest Coverage Ratio = -2.48k (Ebit TTM -131.4m / Interest Expense TTM 53.0k)
EV/FCF = -12.49x (Enterprise Value 1.42b / FCF TTM -113.4m)
FCF Yield = -8.01% (FCF TTM -113.4m / Enterprise Value 1.42b)
FCF Margin = -1.52k% (FCF TTM -113.4m / Revenue TTM 7.47m)
Net Margin = -1.74k% (Net Income TTM -129.9m / Revenue TTM 7.47m)
Gross Margin = 84.51% ((Revenue TTM 7.47m - Cost of Revenue TTM 1.16m) / Revenue TTM)
Gross Margin QoQ = none% (prev 94.55%)
Tobins Q-Ratio = 4.72 (Enterprise Value 1.42b / Total Assets 300.4m)
Interest Expense / Debt = 0.08% (Interest Expense 53.0k / Debt 68.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -103.8m (EBIT -131.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.44 (Total Current Assets 282.2m / Total Current Liabilities 24.7m)
Debt / Equity = 0.32 (Debt 68.6m / totalStockholderEquity, last quarter 211.9m)
Debt / EBITDA = 1.24 (negative EBITDA) (Net Debt -161.2m / EBITDA -130.2m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -161.2m / FCF TTM -113.4m)
Total Stockholder Equity = 231.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.21% (Net Income -129.9m / Total Assets 300.4m)
RoE = -13.18% (Net Income TTM -129.9m / Total Stockholder Equity 985.4m)
RoCE = -12.70% (EBIT -131.4m / Capital Employed (Equity 985.4m + L.T.Debt 49.0m))
RoIC = -52.11% (negative operating profit) (NOPAT -103.8m / Invested Capital 199.2m)
WACC = 14.44% (E(1.58b)/V(1.65b) * Re(15.07%) + D(68.6m)/V(1.65b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 15.07% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 34.89%
[DCF] Fair Price = unknown (Cash Flow -113.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.47 | # QB: 0
Revenue Correlation: -72.40 | Revenue CAGR: -21.37% | SUE: -0.49 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=-7.32% | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=-4.89% | Revisions=+20% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.44 | Chg30d=-14.58% | Revisions=+0% | GrowthEPS=-38.4% | GrowthRev=-81.1%
EPS next Year (2027-12-31): EPS=-0.44 | Chg30d=-8.59% | Revisions=-33% | GrowthEPS=-0.6% | GrowthRev=+1512.6%
[Analyst] Revisions Ratio: -33%